Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Thursday, October 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health presented new data at the ACG 2026 Annual Meeting, highlighting the effectiveness of their blood-based test in improving colorectal cancer screening adherence. The study projected significant benefits for individuals aged 45 to 75, suggesting that blood tests could lead to more follow-up colonoscopies and ultimately reduce CRC mortality rates.

Market Sentiment Analysis

POSITIVE FACTORS

  • Demonstrated effectiveness of blood-based testing for CRC screening.
  • Increased adherence to follow-up colonoscopy.
  • Potential to avert colorectal cancer deaths.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Tennessee. A modeling study looking at individuals 45 to 75 over a lifetime projected

Frequently Asked Questions

What did Guardant Health present at the ACG 2026 meeting?

Guardant Health presented data on the effectiveness of their blood-based test for CRC screening.

How does the blood test impact CRC screening adherence?

The blood test significantly increases adherence to colorectal cancer screening and follow-up colonoscopy.

What age group was studied for the blood test's effectiveness?

The study focused on individuals aged 45 to 75.

What potential benefit does the blood test offer?

It has the potential to avert colorectal cancer deaths.

ShareAdd on Google
Tags: GH Guardant Health CRC screening blood test colorectal cancer ACG 2026
Last updated: Oct 15, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~52 mo
Minimal dilution risk